What Zimmer Biomet's FY2025 10-K says: 9 signals
Zimmer Biomet filed its latest 10-K with the SEC on Feb 19, 2026. It discusses compliance burden, cybersecurity investment and inventory issue.
Public (ZBH)Medical Equipment Manufacturing10,000+ employeeszimmerbiomet.comLinkedIn
- Filed
- Feb 19, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Zimmer Biomet's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 9 signals
Facing EU MDR and UK MDR compliance deadlines between 2026 and 2028.
The company must recertify products under the new, more stringent EU Medical Device Regulation (MDR) by Dec 2027/2028 and adapt to new UK regulations, creating a significant need for regulatory consulting, quality management systems, and data tracking to avoid market disruption.
Facing 2027/2028 deadline to certify all EU products under new stringent MDR regulations.
The company must recertify all products sold in the EU from the old MDD standard to the new, more stringent EU MDR.
Facing emerging FDA oversight for new products using AI and machine learning.
The company's strategic push into AI, machine learning, and Software as a Medical Device (SaaMD) is subject to new and evolving FDA regulations.
artificial intelligencemachine learning
Managing complex consignment inventory model that accounts for 85% of net sales.
With 85% of sales coming from consigned inventory held at customer sites or with sales agents, the company faces significant challenges in inventory tracking, demand forecasting, and optimization.
85%
of net sales from consignment inventory in 2025
Company expands its ROSA® Robot system for use in knee, hip, and shoulder surgeries.
Zimmer Biomet is leveraging its ROSA® Robot across its key Knee, Hip, and S.E.T.
robotics
Facing emerging FDA oversight for AI/ML and software as a medical device products.
As Zimmer Biomet incorporates more AI/ML into its products, it faces new and evolving FDA regulations for data security and cyber risk management.
AImachine learning
Facing pricing pressure from government-sponsored healthcare systems in EMEA and APAC.
Sales in key international markets like Europe and Asia are heavily influenced by government budgets, which creates ongoing pricing and margin pressure.
Subject to increasing data privacy and cyber risk regulations for medical devices.
The company's digital platforms, which collect health-related patient data, are subject to evolving and complex data privacy and cybersecurity laws.
data privacycyber risk management
The company operates a significant global R&D network with approximately 2,000 employees in facilities across the US, Canada, Switzerland, and China.
Signal API · MCP
Track Zimmer Biomet with the Signal API
One POST /v1/companies/enrich call with zimmerbiomet.com returns Zimmer Biomet 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"zimmerbiomet.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Zimmer Biomet 10-K
When did Zimmer Biomet file its latest 10-K?
What does Zimmer Biomet's latest 10-K say about compliance burden?
Where can I find Zimmer Biomet's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .